F tier · safety concern
No published randomised controlled trial has ever tested the injected methionine-inositol-choline blend itself for fat loss, and the products are unapproved compounded mixtures of variable composition.
lipotropic injection blends
Lipotropic blends combine methionine, inositol and choline — sometimes with L-carnitine or B12 — in a compounded injectable marketed for fat loss. The individual nutrients have defined roles in hepatic lipid handling, but the blend as injected appears never to have been evaluated in a controlled human trial.
the explanation
These are mixed vitamin-and-amino-acid shots sold at clinics as fat-loss injections. The ingredients matter for liver metabolism when someone is genuinely deficient, but there is no published trial showing the injection makes people lose fat.
regulatory status
Unapproved / compounded
No lipotropic MIC blend holds FDA, EMA or MHRA marketing authorisation for fat loss; products are prepared by compounding pharmacies. In April 2010 the FDA issued seven warning letters to medical spas and a Brazilian supplier over injectable 'lipodissolve'/mesotherapy fat-elimination drugs, stating the products 'have not been evaluated or approved by the FDA for this use'.
how it works · proposed mechanism
The rationale is borrowed from hepatic lipid-export biochemistry rather than from any demonstrated effect on adipose tissue.
Hepatic phosphatidylcholine and VLDL export
Choline is required for phosphatidylcholine synthesis, which packages hepatic triglyceride into VLDL for export. NIH ODS describes phosphatidylcholine as essential for transporting lipids out of the liver, and severe dietary choline restriction produces reversible liver dysfunction in humans.
One-carbon methyl donor pool
Methionine supplies S-adenosylmethionine, the methyl donor used in the phosphatidylethanolamine N-methyltransferase route to phosphatidylcholine. Combined methionine and choline restriction is the standard way to induce steatohepatitis in laboratory rodents.
Inositol and carnitine additions
Myo-inositol is a precursor for phosphoinositide signalling lipids, and L-carnitine shuttles long-chain fatty acyl groups into mitochondria for beta-oxidation. Neither role has been shown to translate into clinically meaningful fat loss when the compounds are injected.
what’s reported
evidence shape
6 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
The nutrient science is genuine but it is the science of correcting deficiency, and it has been transplanted onto a product tested only in people who are already replete. Where clinic case series report weight loss, participants were almost always simultaneously calorie-restricted or on a GLP-1 receptor agonist, which leaves no way to attribute the change to the injection.
key published findings
- Rodent: methionine- and choline-deficient diets reliably induce hepatic steatosis and steatohepatitis in C57BL/6N mice across three vendor substrains — the model that gave 'lipotropic' its name is a liver-injury model, not an adipose-loss model (Lab Anim Res, 2017).
- Human trial: in controlled feeding studies summarised by NIH ODS, 37 of 57 adults fed under 50 mg choline per 70 kg per day developed liver dysfunction that normalised on choline repletion, establishing choline's hepatic role but only in frank deprivation.
- Human trial: oral betaine 20 g/day for 12 months in NAFLD (n=55 randomised, 34 with paired biopsies) reduced steatosis grade but produced no change in NAFLD activity score or fibrosis stage (Abdelmalek, Hepatology, 2009) — the closest methyl-donor RCT is largely negative on hard endpoints.
- Human trial (indirect route mismatch): meta-analysis of 9 RCTs and 911 participants of ORAL L-carnitine found a mean difference of -1.33 kg (95% CI -2.09 to -0.57) and -0.47 kg/m2 BMI, with the effect diminishing significantly over treatment duration (Pooyandjoo, Obes Rev, 2016).
- Official: FDA's April 2010 enforcement action against injectable lipodissolve/mesotherapy cited adverse reports including permanent scarring and skin deformation alongside the finding that the products were unapproved for fat elimination.
limitations of the evidence
- No randomised, placebo-controlled trial of the injected methionine-inositol-choline combination for body composition has been published; the evidence base is inference from nutrient-deficiency physiology.
- Composition varies between compounding pharmacies, so 'MIC', 'Lipo-B' and 'Lipo-C' do not denote a fixed, comparable product across studies or clinics.
- Clinic-reported outcomes are uncontrolled and confounded by concurrent caloric restriction, exercise programmes and incretin drugs.
documented safety signals
- Injection-site pain, erythema, bruising and induration are commonly reported with repeated intramuscular administration.
- Compounded sterile injectables carry documented contamination and potency-variance risks because they are not subject to pre-market regulatory review.
- NIH ODS attributes fishy body odour, vomiting, excessive sweating and salivation, hypotension and hepatotoxicity to excessive choline intake, with a tolerable upper intake level of 3,500 mg/day in adults.
- FDA has received reports of permanent scarring and skin deformation following injectable lipolytic/mesotherapy procedures.
identity
| full name | Methionine / Inositol / Choline compounded lipotropic injection blends |
| category | Cosmetic |
| modality | other |
laboratory handling
| storage | Compounded aqueous vials are typically supplied refrigerated at 2-8 C and protected from light, with beyond-use dates set by the compounding pharmacy rather than by a stability dossier; no standardised manufacturer stability data exists. |
| solubility | Choline chloride, inositol and L-methionine are all freely water-soluble; L-carnitine is highly water-soluble and hygroscopic. The blends are aqueous solutions, usually pH-adjusted, with no lipophilic depot component. |
| co-studied with | Commercial variants frequently add cyanocobalamin (giving the mixture a red colour and a separate marketing claim) or L-carnitine; because no controlled trial exists for any variant, the incremental contribution of each added component is unquantified. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
6 citedU.S. Food and Drug Administration (news release) · 2010 · official
NIH Office of Dietary Supplements · 2025 · official
U.S. Food and Drug Administration · 2023 · official
Hepatology · 2009 · randomized
Obesity Reviews · 2016 · reviews
Laboratory Animal Research · 2017 · preclinical
others in Cosmetic